Summit Trail Advisors LLC Invests $214,000 in iCAD, Inc. (NASDAQ:ICAD)

Summit Trail Advisors LLC bought a new stake in iCAD, Inc. (NASDAQ:ICAD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 117,000 shares of the technology company's stock, valued at approximately $214,000. Summit Trail Advisors LLC owned about 0.44% of iCAD at the end of the most recent quarter.

Separately, waypoint wealth counsel increased its stake in shares of iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock valued at $26,000 after acquiring an additional 4,400 shares during the last quarter. Hedge funds and other institutional investors own 24.61% of the company's stock.

iCAD Price Performance

iCAD stock traded down $0.29 during mid-day trading on Friday, reaching $3.32. 486,489 shares of the company were exchanged, compared to its average volume of 729,215. The company has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $1.90. The firm has a market cap of $88.11 million, a PE ratio of -25.54 and a beta of 1.47. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of iCAD from a "hold" rating to a "sell" rating in a research note on Wednesday.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.